BeOne Medicines (BEIGF) Net Income towards Common Stockholders Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Net Income towards Common Stockholders Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 7.59% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 151.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 151.28% |
| Mar 31, 2026 | 17,802.13% |
| Dec 31, 2025 | 143.79% |
| Sep 30, 2025 | 202.88% |
| Jun 30, 2025 | 178.34% |
| Mar 31, 2025 | 100.51% |
| Dec 31, 2024 | 58.68% |
| Sep 30, 2024 | -156.33% |
| Jun 30, 2024 | 68.41% |
| Mar 31, 2024 | 27.92% |
| Dec 31, 2023 | 17.47% |
| Sep 30, 2023 | 138.64% |
| Jun 30, 2023 | 32.63% |
| Mar 31, 2023 | 19.94% |
| Dec 31, 2022 | 24.61% |
| Sep 30, 2022 | -27.26% |
| Jun 30, 2022 | -17.78% |
| Mar 31, 2022 | -754.48% |
| Dec 31, 2021 | -17.97% |
| Sep 30, 2021 | -2.69% |